Grail Q3 net loss widens 16% to $103.6 million

By Public Technologies
  • Grail’s third-quarter 2026 net loss widened 16% year-over-year to $103.6 million.
  • Total revenue rose to $37.5 million, while Galleri revenue climbed 14% year-over-year to $37.3 million.
  • Galleri test volume increased approximately 24% year-over-year to more than 56,000 tests.
  • An FDA advisory panel backed Galleri approval in September; a regulatory decision is expected by early Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA89225) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.